|
1
|
Loyo-Varela M, Herrada-Pineda T,
Revilla-Pacheco F and Manrique-Guzman S: Pituitary tumor surgery:
Review of 3004 cases. World Neurosurg. 79:331–336. 2013. View Article : Google Scholar
|
|
2
|
Salehi F, Kovacs K, Scheithauer BW, Lloyd
RV and Cusimano M: Pituitary tumor-transforming gene in endocrine
and other neoplasms: A review and update. Endocr Relat Cancer.
15:721–743. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Boutros C, Cheng-Robles D and Goldenkranz
R: Intestinal neuroendocrine tumor in a patient with pituitary
adenoma. A case report and review of the current screening
recommendations. J Med Case Rep. 1:1402007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sogani J, Yang W, Lavi E, Zimmerman RD and
Gupta A: Sellar collision tumor involving metastatic lung cancer
and pituitary adenoma: Radiologic-pathologic correlation and review
of the literature. Clin Imaging. 38:318–321. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ironside JW: Best practice No 172:
Pituitary gland pathology. J Clin Pathol. 56:561–568. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nistor RF: Parasellar classification of
pituitary adenomas. Neurosurgery. 35:542–544. 1994.PubMed/NCBI
|
|
7
|
Kovacs K, Horvath E and Vidal S:
Classification of pituitary adenomas. J Neurooncol. 54:121–127.
2001. View Article : Google Scholar
|
|
8
|
Sánchez-Tejada L, Sánchez-Ortiga R,
Moreno-Pérez O, Montañana CF, Niveiro M, Tritos NA and Alfonso AM:
Pituitary tumor transforming gene and insulin-like growth factor 1
receptor expression and immunohistochemical measurement of Ki-67 as
potential prognostic markers of pituitary tumors aggressiveness.
Endocrinol Nutr. 60:358–367. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matsuno A, Teramoto A, Takekoshi S, Sanno
N, Osamura RY and Kirino T: Expression of plurihormonal mRNAs in
somatotrophic adenomas detected using a nonisotopic in situ
hybridization method: Comparison with lactotrophic adenomas. Hum
Pathol. 26:272–279. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baskar R, Lee KA, Yeo R and Yeoh KW:
Cancer and radiation therapy: Current advances and future
directions. Int J Med Sci. 9:193–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bergmann-Leitner ES, Duncan EH and Leitner
WW: Identification and targeting of tumor escape mechanisms: A new
hope for cancer therapy? Curr Pharm Des. 9:2009–2023. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ahmed S, Pahwa P, Fields A,
Chandra-Kanthan S, Iqbal N, Zaidi A, Reeder B, Plaza FA, Zhu T and
Leis A: Predictive factors of the use of systemic therapy in stage
iv colorectal cancer: Who gets chemotherapy? Oncology. 88:289–297.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Voloshin T, Voest EE and Shaked Y: The
host immunological response to cancer therapy: An emerging concept
in tumor biology. Exp Cell Res. 319:1687–1695. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rini BI, Weinberg V, Fong L, Conry S,
Hershberg RM and Small EJ: Combination immunotherapy with prostatic
acid phosphatase pulsed antigen-presenting cells (provenge) plus
bevacizumab in patients with serologic progression of prostate
cancer after definitive local therapy. Cancer. 107:67–74. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thara E, Dorff TB, Pinski JK and Quinn DI:
Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer.
Maturitas. 69:296–303. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mao Q, Li L, Zhang C, Sun Y, Liu S and Cui
S: Clinical effects of immunotherapy of DC-CIK combined with
chemotherapy in treating patients with metastatic breast cancer.
Pak J Pharm Sci. 28(3 Suppl): 1055–1058. 2015.PubMed/NCBI
|
|
17
|
Shi YJ, Ren HY, Cen XN, Dong YJ, Ma MX,
Zhao YL, Zhu Y and Yu JR: Dendritic cells elicit cellular immune
response by targeting to capture breast cancer cells. Zhonghua
zhong liu za zhi. 30:107–111. 2008.In Chinese. PubMed/NCBI
|
|
18
|
Chen W, Rains N, Young D and Stubbs RS:
Dendritic cell-based cancer immunotherapy: Potential for treatment
of colorectal cancer? J Gastroenterol Hepatol. 15:698–705. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carmi Y, Spitzer MH, Linde IL, Burt BM,
Prestwood TR, Perlman N, Davidson MG, Kenkel JA, Segal E, Pusapati
GV, et al: Allogeneic IgG combined with dendritic cell stimuli
induce antitumour T-cell immunity. Nature. 521:99–104. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ahmed Ali HA, Di J, Mei W, Zhang YC, Li Y,
Du ZW and Zhang GZ: Antitumor activity of lentivirus-mediated
interleukin -12 gene modified dendritic cells in human lung cancer
in vitro. Asian Pac J Cancer Prev. 15:611–616. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bilusic M, Heery C and Madan RA:
Immunotherapy in prostate cancer: Emerging strategies against a
formidable foe. Vaccine. 29:6485–6497. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pardoll D and Drake C: Immunotherapy earns
its spot in the ranks of cancer therapy. J Exp Med. 209:201–0209.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Corfield AP: Mucins: A biologically
relevant glycan barrier in mucosal protection. Biochim Biophys
Acta. 1850:236–252. 2015. View Article : Google Scholar
|
|
24
|
Kao CJ, Wurz GT, Monjazeb AM, Vang DP,
Cadman TB, Griffey SM, Wolf M and DeGregorio MW: Antitumor effects
of cisplatin combined with tecemotide immunotherapy in a human MUC1
transgenic lung cancer mouse model. Cancer Immunol Res. 2:581–589.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pérez-Sánchez J, Estensoro I, Redondo MJ,
Calduch-Giner JA, Kaushik S and Sitjà-Bobadilla A: Mucins as
diagnostic and prognostic biomarkers in a fish-parasite model:
Transcriptional and functional analysis. PLoS One. 8:e654572013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Asano R, Takemura S, Tsumoto K, Sakurai N,
Teramae A, Ebara S, Katayose Y, Shinoda M, Suzuki M, Imai K, et al:
Functional construction of the anti-mucin core protein (MUC1)
antibody MUSE11 variable regions in a bacterial expression system.
J Biochem. 127:673–679. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cao X, Zhang W, Wan T, He L, Chen T, Yuan
Z, Ma S, Yu Y and Chen G: Molecular cloning and characterization of
a novel CXC chemokine macrophage inflammatory protein-2 gamma
chemoattractant for human neutrophils and dendritic cells. J
Immunol. 165:2588–2595. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Costa CI, Delgado IF, de Costa JA, de
Carvalho RF, Mouta Sda S Jr, Vianna CO and de Moraes MT:
Establishment and validation of an ELISA for the quantitation of
HBsAg in recombinant hepatitis B vaccines. J Virol Methods.
172:32–037. 2011. View Article : Google Scholar
|
|
29
|
Jones N, Agrawal D, Elrefaei M, Hanson A,
Novitsky V, Wong JT and Cao H: Evaluation of antigen-specific
responses using in vitro enriched T cells. J Immunol Methods.
274:139–147. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Holdsworth SR, Kitching AR and Tipping PG:
Th1 and Th2 T helper cell subsets affect patterns of injury and
outcomes in glomerulonephritis. Kidney Int. 55:1198–1216. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Muraille E and Leo O: Revisiting the
Th1/Th2 paradigm. Scand J Immunol. 47:1–9. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mishra J, Drummond J, Quazi SH, Karanki
SS, Shaw JJ, Chen B and Kumar N: Prospective of colon cancer
treatments and scope for combinatorial approach to enhanced cancer
cell apoptosis. Crit Rev Oncol Hematol. 86:232–250. 2013.
View Article : Google Scholar :
|
|
33
|
Kirkwood JM, Moschos S and Wang W:
Strategies for the development of more effective adjuvant therapy
of melanoma: Current and future explorations of antibodies,
cytokines, vaccines, and combinations. Clin Cancer Res. 12(Suppl):
S2331–S2336. 2006. View Article : Google Scholar
|
|
34
|
Kirkwood JM, Strawderman MH, Ernstoff MS,
Smith TJ, Borden EC and Blum RH: Interferon alfa-2b adjuvant
therapy of high-risk resected cutaneous melanoma: The eastern
cooperative oncology group trial EST 1684. J Clin Oncol. 14:7–17.
1996.PubMed/NCBI
|
|
35
|
Terando A, Sabel MS and Sondak VK:
Melanoma: Adjuvant therapy and other treatment options. Curr Treat
Options Oncol. 4:187–199. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Krishnan L, Deschatelets L, Stark FC,
Gurnani K and Sprott GD: Archaeosome adjuvant overcomes tolerance
to tumor-associated melanoma antigens inducing protective CD8 T
cell responses. Clin Dev Immunol. 2010:5784322010. View Article : Google Scholar
|
|
37
|
Mechl Z and Kopecny J: Current results
with surgery and adjuvant chemotherapy in malignant melanoma. Arch
Geschwulstforsch. 56:367–371. 1986.In German.
|
|
38
|
Inao T, Harashima N, Monma H, Okano S,
Itakura M, Tanaka T, Tajima Y and Harada M: Antitumor effects of
cytoplasmic delivery of an innate adjuvant receptor ligand, poly
(I:C), on human breast cancer. Breast Cancer Res Treat. 134:89–100.
2012. View Article : Google Scholar
|
|
39
|
Huang YK, Zheng Z, Cheng CX, Wang LY, Li
YR and Qiu F: The antitumor effect of the toll-like receptor 3
ligand polyinosinic-cytidylic acid as an adjuvant. Cancer Immunol
Immunother. 62:237–244. 2013. View Article : Google Scholar
|
|
40
|
Martinez-Gil L, Goff PH, Hai R,
Garcia-Sastre A, Shaw ML and Palese P: A Sendai virus-derived RNA
agonist of RIG-I as a virus vaccine adjuvant. J Virol.
87:1290–1300. 2013. View Article : Google Scholar :
|
|
41
|
Ebner S, Ratzinger G, Krosbacher B,
Schmuth M, Weiss A, Reider D, Kroczek RA, Herold M, Heufler C,
Fritsch P and Romani N: Production of IL-12 by human
monocyte-derived dendritic cells is optimal when the stimulus is
given at the onset of maturation, and is further enhanced by IL-4.
J Immunol. 166:633–641. 2001. View Article : Google Scholar
|
|
42
|
Lindstedt M, Johansson-Lindbom B and
Borrebaeck CA: Global reprogramming of dendritic cells in response
to a concerted action of inflammatory mediators. Int Immunol.
14:1203–1213. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang Y, Ochando J, Yopp A, Bromberg JS and
Ding Y: IL-6 plays a unique role in initiating c-Maf expression
during early stage of CD4 T cell activation. J Immunol.
174:2720–2729. 2005. View Article : Google Scholar : PubMed/NCBI
|
